NanoSphere researches , develops and commercializes a diverse line of product formulations based on the NanoSphere Delivery System™ to meet the needs of healthcare providers , consumers and suppliers . The NanoSphere Delivery System™ is the first to apply nanotechnology to improve the bioavailability and efficacy of essential ingredients and medications . This disruptive technology introduces a significant advancement in these industries . NHS is the only nanotechnology company who plans to offer vertically integrated , commercial lines .
Left : Evolve Formulas ’ game-changing transdermal product NanoSerum™ , enables cannabis to be rapidly absorbed into systemic circulation for direct-focus relief from pain , inflammation and anxiety .
Strategic Direction
NanoSphere ’ s initial product deployment is for the cannabinoid market , targeting both the medical marijuana market and , where legalized , the recreational usage market . NanoSphere has already partnered with a licensee in Colorado , and in late spring 2017 launched its first award-winning cannabinoid product line , branded Evolve NanoSerum , in the Colorado market . NanoSphere will further license its intellectual property and proprietary manufacturing method to selected cannabis cultivators , extractors and distributors on a state-by-state basis and abroad , and is currently in discussions with operators in several states to replicate the business model in Colorado . Other planned future deployments include nutraceuticals , nonsteroidal anti-inflammatory drugs and animal health applications .
Technology & Innovation
NanoSphere has developed a revolutionary , multiple patent-pending method for the non-invasive delivery of bioactive compounds , such as cannabinoids , nutraceuticals , pharmaceuticals and over-the-counter medications , into the body with greater efficiency than many traditional delivery systems . The NanoSphere Delivery System™ encapsulates these compounds in protective nano-sized spheres for transport directly into the bloodstream and cells . Our ongoing research and successful pharmacokinetic blood studies of our technology have confirmed the greater bioavailability , bioactivity and efficacy of our delivery system .
Intellectual Property Overview
Our patent-pending portfolio includes : U . S . patent-pending 61 / 890,773 : Nutraceutical Delivery Utilizing Nano Particle Compositions , 62 / 091,994 : Nanoparticle Encapsulation To Treat And Prevent Global Inflammation And Pain , 62 / 130,775 : Lipid Nanoparticle Compositions and Methods as Carriers of Cannabinoids .
CSE : NSHS